Journal of Ophthalmology / 2020 / Article / Tab 4

Research Article

Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis

Table 4

Effect of treatment on BCVA, CMT, and TMV values in vitrectomized eyes (n = 11).

Mean ± SDF value valuePartial eta2

BCVA (logMAR)
Baseline0.70 ± 0.304.3040.0380.301
6th month0.56 ± 0.28
12th month0.51 ± 0.32
18th month0.41 ± 0.28
24th month0.44 ± 0.24

CMT (μm)
Baseline330 ± 956.1220.0050.380
6th month300 ± 106
12th month272 ± 85
18th month211 ± 96
24th month221 ± 117

TMV (mm3)
Baseline9.35 ± 1.524.4670.0300.309
6th month8.62 ± 0.86
12th month8.52 ± 0.91
18th month8.29 ± 1.08
24th month8.25 ± 1.47

BCVA was measured with a standard Snellen chart and converted to the logarithm of the minimum angle of resolution (logMAR) units. BCVA indicates best-corrected visual acuity; CMT, central macular thickness; SD, standard deviation; TMV, total macular volume. Repeated measure ANOVA. None of the pairwise comparisons for BCVA, CMT, and TMV values were significant in the vitrectomized group.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.